Busey Bank Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Busey Bank increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 23,331 shares of the company’s stock after purchasing an additional 269 shares during the period. Busey Bank’s holdings in Eli Lilly and Company were worth $20,670,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. M&G Plc purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $8,896,000. Virtu Financial LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $2,138,000. China Universal Asset Management Co. Ltd. boosted its position in Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares during the period. Mutual Advisors LLC boosted its position in Eli Lilly and Company by 404.8% in the 1st quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after buying an additional 50,197 shares during the period. Finally, Private Advisor Group LLC boosted its position in Eli Lilly and Company by 0.6% in the 1st quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock valued at $59,345,000 after buying an additional 430 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on LLY shares. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Finally, Barclays raised their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,013.41.

Eli Lilly and Company Trading Up 0.1 %

NYSE LLY opened at $892.51 on Friday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market cap of $848.27 billion, a PE ratio of 109.92, a P/E/G ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a one year low of $547.61 and a one year high of $972.53. The firm’s fifty day moving average is $920.32 and its two-hundred day moving average is $860.96.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Analysts expect that Eli Lilly and Company will post 14.05 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.